Navigation Links
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
Date:12/6/2012

ng infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include phase II studies for cervical dysplasia, leukemia and hepatitis C virus and phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support contin
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
5. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... 2014 The Registration Committee today ... now open for Pittcon 2015, the world’s largest ... event will be held March 8-12, 2015, at ... , The discounted registration fee of $175 ... 2/20/2015). This affordable price includes unlimited week-long access ...
(Date:9/11/2014)... September 11, 2014 ... production of its biocompatible, non-toxic and non-leaching antimicrobial Sanipolymers™. ... as one of the top tech startups of ... biomimetics to create antimicrobial plastics. Consumers are ... touch surfaces use hazardous substances. These substances or additives ...
(Date:9/11/2014)... (PRWEB) September 11, 2014 DuPont ... excited to announce that it has appointed ... two wholly owned subsidiaries, Essex Grain Products ... of Zemea® USP propanediol in the food and ... following USA eastern and mid-western states: Alabama, ...
(Date:9/10/2014)... 11, 2014 Daten ... der Jahresversammlung der Europäischen Gesellschaft für gynäkologische ... Tumorprofilierung als "Wendepunkt" für Onkologen. ... ein deutlich längeres Überleben nach der Profilierung ... peritonealem Krebs, denen Behandlungen verabreicht wurden, die ...
Breaking Biology Technology:Conferee Registration Opens for Pittcon 2015; Housing & Travel Open for Reservations 2World's First Biocompatible and Non-toxic Antibacterial Plastic 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 2Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 4Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 5
... Ocean energy company, BioPower Systems (BPS), today announced ... Hon. Michael O,Brien MP, has awarded the company conditional ... Pilot Demonstration Program. The funding will be ... company,s 250kW bioWAVE ocean wave energy system at a ...
... RSB Spine announced today that it received a revised ... an interbody implant with integrated fixation and an anterior ... for stand-alone interbody devices with integrated fixation.   The new ... new code for cervical interbody devices is OVE.   In ...
... 30, 2011  Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology ... Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced ... publishing a mechanism study on the use of Alpha-Cobratoxin, ... pain. The paper was co-authored by Paul Reid, PhD ...
Cached Biology Technology:BioPower Systems Awarded $5 Million from Victorian Government 2BioPower Systems Awarded $5 Million from Victorian Government 3FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation 2Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain 2Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain 3
(Date:9/12/2014)... an active role in the destruction and remodelling ... being an ,innocent bystander, as previously thought. , ... Lawler, Dr Ben Croker and colleagues from the ... while investigating the role of the protein SOCS3 ... was published in the journal Arthritis and ...
(Date:9/12/2014)... coccidiosis is a serious parasitic infection of young ... to diarrhoea and reduced nutritional intake. As the ... can result in increased mortality, the disease is ... farms., "The developing immune system of neonatal piglets ... the parasites. For this reason, an infection shortly ...
(Date:9/11/2014)... with autism often show a reduced frequency of ... in repetitive solitary behaviors. Autism has also been ... structure involved in processing emotions. Now Caltech researchers ... amygdala that control whether the animal engages in ... may have implications for understanding neural circuit dysfunctions ...
Breaking Biology News(10 mins):No innocent bystander: Cartilage contributes to arthritis 2Piglet health 2Piglet health 3Tipping the balance of behavior 2Tipping the balance of behavior 3
... the late 1800s, a flurry of fossil speculation across the ... Bone Wars. Drawn into the spectacle were two scientists ... acclaimed as the Father of Texas Geology, and naturalist Jacob ... Hill and Boll had supporting roles in the Bone ...
... to the amount of unhealthy foods they eat, but can ... new study in the Journal of Consumer Research . ... willpower and desire, consumers can,t rely entirely on willpower to ... will make them lose interest in food. One way is ...
... side-effects caused by the anti-parasitic drug quinine in the treatment ... The research, carried out by Nottingham scientists on the University,s ... in our levels of the amino acid, tryptophan, has a ... appears that the lower our levels of tryptophan the more ...
Cached Biology News:Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 2Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 3Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 4Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 5Eat dessert first? It might help you control your diet 2Diet could combat adverse side-effects of quinine 2Diet could combat adverse side-effects of quinine 3
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Indoleamine 2,3-dioxygenase [IDO]...
Request Info...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: